Get the Stockscreener App
7.94
3.52%
-0.29
After Hours:
7.91
-0.03
-0.38%
Ars Pharmaceuticals Inc stock is traded at $7.94, with a volume of 2.48M.
It is down -3.52% in the last 24 hours and down -5.48% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
See More
Previous Close:
$8.23
Open:
$8.23
24h Volume:
2.48M
Relative Volume:
1.56
Market Cap:
$788.47M
Revenue:
$84.28M
Net Income/Loss:
$-171.30M
P/E Ratio:
-4.5703
EPS:
-1.7373
Net Cash Flow:
$-171.21M
1W Performance:
+6.94%
1M Performance:
-5.48%
6M Performance:
+4.61%
1Y Performance:
-45.32%
1-Day Range:
$7.91
$8.29
1-Week Range:
$7.08
$8.36
52-Week Range:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
7.94 | 817.27M | 84.28M | -171.30M | -171.21M | -1.7373 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Northland Capital | Outperform |
| Nov-04-25 | Resumed | Roth Capital | Buy |
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
Number of shareholders of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Risks - TipRanks
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2026 Earnings Call Transcript - Insider Monkey
ARS Pharmaceuticals gears up for Q1 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
ARS Pharma (SPRY) Q1 2026 Earnings Transcript - The Globe and Mail
Why (SPRY) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ARS Pharmaceuticals, Inc. (SPRY) reports Q1 loss, beats revenue estimates - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Q1 earnings call highlights - MSN
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program - MSN
Transcript : ARS Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 15, 2026 - marketscreener.com
ARS Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
ARS Pharma (SPRY) Q4 2025 Earnings Transcript - The Globe and Mail
ARS Pharmaceuticals 2026 Q1 10-Q: Financial Results, neffy™ Commercialization, and Key Risk Factors - Minichart
Rubric Capital (SPRY) reports 8.06% stake; 8,000,000 shares disclosed - Stock Titan
ARS Pharmaceuticals Q1 2026 Results: neffy® Drives $22.7M Revenue, U.S. and Global Expansion Updates - Minichart
ARS Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
SPRY: Q1 revenue hit $22.7M as neffy adoption surged, with expanded access set to drive further growth - TradingView
Earnings call transcript: ARS Pharmaceuticals misses Q1 2026 EPS forecast, stock drops - Investing.com
ARS Pharmaceuticals Delivers 185% Revenue Growth in Q1 2026 - AlphaStreet
ARS Pharmaceuticals earnings missed by $0.12, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ARS Pharmaceuticals stock rises 2% on revenue beat despite earnings miss By Investing.com - Investing.com South Africa
ARS Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment - ChartMill
ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion - TipRanks
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
ARS Pharmaceuticals Q1 Loss Widens, Revenue Rises; Shares Up Pre-Bell - Moomoo
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update - Investing News Network
ARS PHARMACEUTICALS ($SPRY) Releases Q1 2026 Earnings - Quiver Quantitative
ARS Pharmaceuticals 1Q 2026: Revenue $22.7M, EPS $(0.61) — 10-Q Summary - TradingView
Neffy launch drives ARS Pharmaceuticals (NASDAQ: SPRY) Q1 revenue jump - Stock Titan
ARS Pharmaceuticals stock rises 2% on revenue beat despite earnings miss - Investing.com
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss - marketscreener.com
ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth - TradingView
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q1 Revenue $22.7M, vs. FactSet Est of $22.2M - marketscreener.com
ARS Pharmaceuticals (NASDAQ: SPRY) grows neffy sales but posts $60.6M Q1 loss - Stock Titan
Press Release: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update - Moomoo
ARS Pharmaceuticals Q1 2026 earnings preview - MSN
What's Driving ARS Pharmaceuticals' Q1 2026 Earnings Narrative - Kavout
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most A - Benzinga
ARS Pharmaceuticals Appoints Donn Casale as New President - The Globe and Mail
ARS Pharma names Donn Casale president - The Pharma Letter
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Sahm
ARS Pharmaceuticals appoints Donn Casale as president By Investing.com - Investing.com India
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ars Pharmaceuticals Inc Stock (SPRY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dorsey Brian | Chief Operating Officer |
Nov 13 '25 |
Sale |
8.71 |
21,828 |
190,050 |
10,789 |
| Chakma Justin | Chief Business Officer |
Nov 12 '25 |
Option Exercise |
0.84 |
30,000 |
25,200 |
166,380 |
| Chakma Justin | Chief Business Officer |
Nov 12 '25 |
Sale |
8.87 |
166,380 |
1,476,147 |
0 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):